Structure-Based Design of Potent Non-Peptide MDM2 Inhibitors
Citations Over TimeTop 10% of 2005 papers
Abstract
A successful structure-based design of a class of non-peptide small-molecule MDM2 inhibitors targeting the p53-MDM2 protein-protein interaction is reported. The most potent compound 1d binds to MDM2 protein with a Ki value of 86 nM and is 18 times more potent than a natural p53 peptide (residues 16-27). Compound 1d is potent in inhibition of cell growth in LNCaP prostate cancer cells with wild-type p53 and shows only a weak activity in PC-3 prostate cancer cells with a deleted p53. Importantly, 1d has a minimal toxicity to normal prostate epithelial cells. Our studies provide a convincing example that structure-based strategy can be employed to design highly potent, non-peptide, cell-permeable, small-molecule inhibitors to target protein-protein interaction, which remains a very challenging area in chemical biology and drug design.
Related Papers
- The expression and significance of p53 and MDM2 protein in basal cell carcinoma(2012)
- EXPRESSION OF MDM2 AND p53 PROTEIN IN ASTROCYTOMAS(2000)
- → Tumor protein p53 (TP53; p53); mdm2 p53 binding protein homolog (MDM2)(2009)
- → Mdm2 p53 binding protein homolog (MDM2); tumor protein p53 (TP53; p53)(2009)
- → Tumor protein p53 (TP53; p53); mdm2 p53 binding protein homolog (MDM2; HDM2)(2010)